29 related articles for article (PubMed ID: 38552544)
1. Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial.
Lai S; Li P; Liu X; Liu G; Xie T; Zhang X; Wang X; Huang J; Tang Y; Liu Z; Shen G; Li C; Lu F; Wang L; Jiang F; Sun C; Chen Y; Chen M
Cancer Biol Med; 2024 Mar; 21(5):433-44. PubMed ID: 38445445
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
Onoi K; Yamada T; Morimoto K; Kawachi H; Tsutsumi R; Takeda T; Okada A; Tamiya N; Chihara Y; Shiotsu S; Takemura Y; Yamada T; Hasegawa I; Katayama Y; Iwasaku M; Tokuda S; Takayama K
Target Oncol; 2024 May; 19(3):411-421. PubMed ID: 38467958
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.
Tamura K; Okuma Y; Nomura S; Fukuda A; Masuda K; Matsumoto Y; Shinno Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):216. PubMed ID: 38668936
[TBL] [Abstract][Full Text] [Related]
4. Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial.
Lin YD; Wu GS; Rao MY; Liu YH; Han YW; Zhang J; Zhang JW
Sci Rep; 2024 May; 14(1):11486. PubMed ID: 38769368
[TBL] [Abstract][Full Text] [Related]
5. The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study.
Lv XM; Liu Y; Feng Y; Liang HL; Zhi WW
J Cancer; 2024; 15(11):3539-3546. PubMed ID: 38817880
[No Abstract] [Full Text] [Related]
6. A Pilot Study of Anlotinib as a Combination Treatment in Advanced Nasopharyngeal Carcinoma.
Zhou R; Zhou P; Yu YF; Lin Q; Wu SG
Curr Cancer Drug Targets; 2024; 24(3):319-327. PubMed ID: 37563818
[TBL] [Abstract][Full Text] [Related]
7. Progression-free survival estimation of docetaxel-based second-line treatment for advanced non-small cell lung cancer: a pooled analysis from 18 randomized control trials.
N C; Jain A; C S; Shreevatsa B; Rajendrasozhan S; Dharmashekar C; Suresh KP; Patil SS; Singh P; Vishwanath P; Srinivasa C; Kollur SP; Shivamallu C
Front Oncol; 2024; 14():1298786. PubMed ID: 38807763
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial.
Zhang C; Chu T; Wang Q; Cheng Y; Zhang Y; Wang R; Ma L; Qian C; Han B; Li K
Cancer Biol Med; 2024 May; ():. PubMed ID: 38809003
[TBL] [Abstract][Full Text] [Related]
9. MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy.
Amery T; Tabatabaei S; Sonpatki M; Beer TM
Anticancer Res; 2024 May; 44(5):2247-2248. PubMed ID: 38677728
[No Abstract] [Full Text] [Related]
10. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
Pu X; Xiao Z; Li J; Wu Z; Ma Z; Weng J; Xiao M; Chen Y; Cao Y; Cao P; Wang Q; Xu Y; Li K; Chen B; Xu F; Liu L; Kong Y; Zhang H; Duan H; Wu L
Lung Cancer; 2024 May; 191():107538. PubMed ID: 38552544
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
